Skip to content
Igovomab
Indimacis (igovomab) is an antibody pharmaceutical. Igovomab was first approved as Indimacis 125 on 1996-10-04. It has been approved in Europe to treat ovarian neoplasms and radionuclide imaging. It is known to target mucin-16.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
diagnosisD003933
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIGOVOMAB
INN—
Description
Igovomab (mouse F(ab')2)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID171656-50-1
RxCUI—
ChEMBL IDCHEMBL2109036
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
Agency Approved
No data
Alternate
MUC16
MUC16
Organism
Homo sapiens
Gene name
MUC16
Gene synonyms
CA125
NCBI Gene ID
94025
Protein name
mucin-16
Protein synonyms
CA-125, CA125 ovarian cancer antigen, cancer antigen 125, Ovarian cancer-related tumor marker CA125, Ovarian carcinoma antigen CA125
Uniprot ID
Q96RK2
Mouse ortholog
Muc16 (73732)
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details